1921
Volume 75, Issue 5
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Most infections are egg-negative after a single dose of oxamniquine. A cohort of 661 infected children was treated at 6-month intervals and assessed for nutritional and parasitological status. Initial biochemical and immunologic markers were measured in a subset of 84 children. All were treated at the start of therapy and at 6 months. Immunoglobulins only served as markers for active infection. No markers were predictive of cure or reinfection, except initial infection intensity and serum low-density lipoprotein. Ten percent were persistently infected and had no change in infection intensity at any time-point. Several factors suggest that this group was biologically different. In addition to failing to reduce their worm burden, they had significantly higher initial intensity of infection (100 versus 65 eggs/g, = 0.001) and significantly lower initial serum low-density lipoprotein (72 versus 104 mg/dL, = 0.045). The biologic plausibility of this observation is discussed.

Loading

Article metrics loading...

/content/journals/10.4269/ajtmh.2006.75.904
2006-11-01
2017-11-20
Loading full text...

Full text loading...

/deliver/fulltext/14761645/75/5/0750904.html?itemId=/content/journals/10.4269/ajtmh.2006.75.904&mimeType=html&fmt=ahah

References

  1. Gryseels B, Nkulikyinka L, Coosemans MH, 1987. Field trials of praziquantel and oxamniquine for the treatment of schistosomiasis mansoni in Burundi. Trans R Soc Trop Med Hyg 81 : 641–644.
  2. Katz N, Rocha RS, de Souza CP, Coura Filho P, Bruce JI, Coles GC, Kinoti GK, 1991. Efficacy of alternating therapy with oxamniquine and praziquantel to treat Schistosoma mansoni in children following failure of first treatment. Am J Trop Med Hyg 44 : 509–512.
  3. van Lieshout L, Stelma FF, Guisse F, Falcao Ferreira ST, Polman K, van Dam GJ, Diakhate M, Sow S, Deelder A, Gryseels B, 1999. The contribution of host-related factors to low cure rates of praziquantel for the treatment of Schistosoma mansoni in Senegal. Am J Trop Med Hyg 61 : 760–765.
  4. Gryseels B, Mbaye A, De Vlas SJ, Stelma FF, Guisse F, Van Lieshout L, Faye D, Diop M, Ly A, Tchuem-Tchuente LA, Engels D, Polman K, 2001. Are poor responses to praziquantel for the treatment of Schistosoma mansoni infections in Senegal due to resistance? An overview of the evidence. Trop Med Int Health 6 : 864–873.
  5. Roberts M, Butterworth AE, Kimani G, Kamau T, Fulford AJ, Dunne DW, Ouma JH, Sturrock RF, 1993. Immunity after treatment of human schistosomiasis: Association between cellular responses and resistance to reinfection. Infect Immun 61 : 4984–4993.
  6. Naus CW, Kimani G, Ouma JH, Fulford AJ, Webster M, van Dam GJ, Deelder AM, Butterworth AE, Dunne DW, 1999. Development of antibody isotype responses to Schistosoma mansoni in an immunologically naive immigrant population: Influence of infection duration, infection intensity, and host age. Infect Immun 67 : 3444–3451.
  7. Abel L, Demenais F, Prata A, Souza AE, Dessein A, 1991. Evidence for the segregation of a major gene in human susceptibility/resistance to infection by Schistosoma mansoni. Am J Hum Genet 48 : 959–970.
  8. Butterworth AE, Capron M, Cordingley JS, Dalton PR, Dunne DW, Kariuki HC, Kimani G, Koech D, Mugambi M, Ouma JH, et al., 1985. Immunity after treatment of human schistosomiasis mansoni. II. Identification of resistant individuals, and analysis of their immune responses. Trans R Soc Trop Med Hyg 79 : 393–408.
  9. Harrison RA, Bickle Q, Doenhoff MJ, 1982. Factors affecting the acquisition of resistance against Schistosoma mansoni in the mouse. Evidence that the mechanisms which mediate resistance during early patent infections may lack immunological specificity. Parasitology 84 : 93–110.
  10. Webster M, Correa-Oliveira R, Gazzinelli G, Viana IR, Fraga LA, Silveira AM, Dunne DW, 1997. Factors affecting high and low human IgE responses to schistosome worm antigens in an area of Brazil endemic for Schistosoma mansoni and hookworm. Am J Trop Med Hyg 57 : 487–494.
  11. Katz N, Chaves A, Pellegrino J, 1972. A simple device for quantitative stool thick-smear technique in schistosomiasis mansoni. Rev Inst Med Trop Sao Paulo 14 : 397–400.
  12. Eberl M, al-Sherbiny M, Hagan P, Ljubojevic S, Thomas AW, Wilson RA, 2002. A novel and sensitive method to monitor helminth infections by faecal sampling. Acta Trop 83 : 183–187.
  13. Assis AM, Barreto ML, Prado MS, Reis MG, Parraga IM, Blanton RE, 1998. Schistosoma mansoni infection and nutritional status in schoolchildren: A randomized, double-blind trial in northeastern Brazil. Am J Clin Nutr 68 : 1247–1253.
  14. Parraga IM, Assis AM, Prado MS, Barreto ML, Reis MG, King CH, Blanton RE, 1996. Gender differences in growth of school-aged children with schistosomiasis and geohelminth infection. Am J Trop Med Hyg 55 : 150–156.
  15. Brito LL, Barreto ML, Silva Rde C, Assis AM, Reis MG, Parraga I, Blanton RE, 2003. Risk factors for iron-deficiency anemia in children and adolescents with intestinal helminthic infections. Rev Panam Salud Publica 14 : 422–431.
  16. Reichenheim ME, Harpham T, 1990. An intra-community profile of nutritional deficiency: a study of children under 5 years of age in a low-income community in Rio de Janeiro (Brizal). Rev Saude Publica 24 : 69–79.
  17. Allain CC, Poon LS, Chan CS, Richmond W, Fu PC, 1974. Enzymatic determination of total serum cholesterol. Clin Chem 20 : 470–475.
  18. Fossati E, Harashina T, Fujino T, 1982. The reapplication of microvascular clamps after venous anastomosis: an experimental study. J Microsurg 3 : 239–241.
  19. Burstein M, Scholnick HR, Morfin R, 1970. Rapid method for the isolation of lipoproteins from human serum by precipitation with polyanions. J Lipid Res 11 : 583–595.
  20. Friedewald WT, Levy RI, Fredrickson DS, 1972. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18 : 499–502.
  21. Li Z, King CL, Ogundipe JO, Licate LS, Blanton RE, 1995. Preferential recognition by human IgE and IgG4 of a species-specific Schistosoma haematobium serine protease inhibitor. J Infect Dis 171 : 416–422.
  22. Skoog T, Dichtl W, Boquist S, Skoglund-Andersson C, Karpe F, Tang R, Bond MG, de Faire U, Nilsson J, Eriksson P, Hamsten A, 2002. Plasma tumour necrosis factor-alpha and early carotid atherosclerosis in healthy middle-aged men. Eur Heart J 23 : 376–383.
  23. Svenungsson E, Fei GZ, Jensen-Urstad K, de Faire U, Hamsten A, Frostegard J, 2003. TNF-alpha: A link between hypertri-glyceridaemia and inflammation in SLE patients with cardiovascular disease. Lupus 12 : 454–461.
  24. Stelma FF, Talla I, Polman K, Niang M, Sturrock RF, Deelder AM, Gryseels B, 1993. Epidemiology of Schistosoma mansoni infection in a recently exposed community in northern Senegal. Am J Trop Med Hyg 49 : 701–706.
  25. Coelho PM, de Mello RT, Gerken SE, 1993. Schistosoma mansoni: Evaluation of the activity of oxamniquine on schistoso-mules, at 24 hours after infection. Rev Inst Med Trop Sao Paulo 35 : 557–561.
  26. Brindley PJ, Sher A, 1987. The chemotherapeutic effect of prazi-quantel against Schistosoma mansoni is dependent on host antibody response. J Immunol 139 : 215–220.
  27. Silva LM, Andrade ZA, 1997. Immunostimulation as adjuvant for the chemotherapy of experimental schistosomiasis. Rev Inst Med Trop Sao Paulo 39 : 11–14.
  28. Fallon PG, Fookes RE, Wharton GA, 1996. Temporal differences in praziquantel- and oxamniquine-induced tegumental damage to adult Schistosoma mansoni: Implications for drug-antibody synergy. Parasitology 112 : 47–58.
  29. Lambertucci JR, Modha J, Doenhoff M, 1989. Schistosoma mansoni: The therapeutic efficacy of oxamniquine is enhanced by immune serum. Trans R Soc Trop Med Hyg 83 : 362–363.
  30. Hansson GK, 2001. Regulation of immune mechanisms in atherosclerosis. Ann N Y Acad Sci 947 : 157–165.
  31. Frezard F, de Melo AL, 1997. Evaluation of the schistosomicidal efficacy of liposome-entrapped oxamniquine. Rev Inst Med Trop Sao Paulo 39 : 97–100.
  32. Chiang CP, Caulfield JP, 1989. Human lipoprotein binding to schistosomula of Schistosoma mansoni. Displacement by polyanions, parasite antigen masking, and persistence in young larvae. Am J Pathol 135 : 1015–1024.
  33. Rogers MV, Henkle KJ, Fidge NH, Mitchell GF, 1989. Identification of a multispecific lipoprotein receptor in adult Schistosoma japonicum by ligand blotting analyses. Mol Biochem Parasitol 35 : 79–88.
  34. Fan J, Gan X, Yang W, Shen L, McManus DP, Brindley PJ, 2003. A Schistosoma japonicum very low-density lipoprotein-binding protein. Int J Biochem Cell Biol 35 : 1436–1451.
  35. Vanhamme L, Paturiaux-Hanocq F, Poelvoorde P, Nolan DP, Lins L, Van Den Abbeele J, Pays A, Tebabi P, Van Xong H, Jacquet A, Moguilevsky N, Dieu M, Kane JP, De Baetselier P, Brasseur R, Pays E, 2003. Apolipoprotein L-I is the trypanosome lytic factor of human serum. Nature 422 : 83–87.
  36. Caldas IR, Correa-Oliveira R, Colosimo E, Carvalho OS, Massara CL, Colley DG, Gazzinelli G, 2000. Susceptibility and resistance to Schistosoma mansoni reinfection: Parallel cellular and isotypic immunologic assessment. Am J Trop Med Hyg 62 : 57–64.
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.2006.75.904
Loading
/content/journals/10.4269/ajtmh.2006.75.904
Loading

Data & Media loading...

  • Received : 10 Aug 2005
  • Accepted : 12 Apr 2006

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error